| Schedule of Reconciliation Consolidated Net Loss |
The following table presents certain
financial data for the Company’s reportable segment and a reconciliation to the Company’s consolidated net loss.
Schedule
of Reconciliation Consolidated Net Loss
| |
|
2024 |
|
|
2023 |
|
| Product Revenue |
|
$ |
- |
|
|
$ |
- |
|
| Product Cost of Sales |
|
|
- |
|
|
|
- |
|
| |
|
|
|
|
|
|
|
|
| Gross Income |
|
|
- |
|
|
|
- |
|
| |
|
|
|
|
|
|
|
|
| Operating Expenses |
|
|
|
|
|
|
|
|
| Administrative
Expenses |
|
|
4,161,907 |
|
|
|
5,442,886 |
|
| Research
and Development Expenses |
|
|
3,441,010 |
|
|
|
7,867,795 |
|
Segment Net Loss |
|
|
(7,602,917 |
) |
|
|
(13,310,681 |
) |
| |
|
|
|
|
|
|
|
|
Reconcilement of Net Loss |
|
|
|
|
|
|
|
|
| Adjustments and Reconciling Items |
|
|
|
|
|
|
|
|
| Stock Based
Compensation |
|
|
1,057,271 |
|
|
|
3,049,537 |
|
| Series
F Warrant Issuance Expenses |
|
|
- |
|
|
|
762,834 |
|
| Series
F-1 Warrant Issuance Expenses |
|
|
539,097 |
|
|
|
- |
|
| Series
G Warrant Issuance Expenses |
|
|
969,505 |
|
|
|
- |
|
| Interest
and Dividend Income |
|
|
351,809 |
|
|
|
455,570 |
|
| Gains on
Sales of Marketable Securities |
|
|
976 |
|
|
|
416 |
|
| Unrealized
Gains on Marketable Securities |
|
|
671 |
|
|
|
514 |
|
| Change
in Fair Value of Derivative Liabilities |
|
|
(388,000 |
) |
|
|
3,088,800 |
|
| Change
in Fair Value of Warrant Liabilities |
|
|
(4,410,000 |
) |
|
|
9,756,000 |
|
| Loss on
Issuance of Series F-1 Convertible Preferred Stock |
|
|
(3,737,000 |
) |
|
|
- |
|
| Loss on
Issuance of Series G Convertible Preferred Stock |
|
|
(5,109,000 |
) |
|
|
- |
|
| Casualty
Gain/(Loss) |
|
|
100,000 |
|
|
|
(178,198 |
) |
| Total Adjustments and Reconciling Items |
|
|
(15,756,417 |
)
|
|
|
9,310,731 |
|
| |
|
|
|
|
|
|
|
|
| Consolidated
Net Loss |
|
$ |
(23,359,334 |
) |
|
$ |
(3,999,950 |
) |
|